Here are the 424B prospectus supplements from BeyondSpring Inc. (BYSI) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow BYSI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BYSI filings page.
BeyondSpring Inc. may offer and sell up to 9,200,000 ordinary shares through Citizens JMP Securities, LLC as agent in an at-the-market offering, with an aggregate offering-price limit of $11,942,800 under current public-float restrictions. At the assumed price of $0.7772 per share, BeyondSpring estimates gross proceeds of approximately $7.15 million; Citizens may receive a commission of up to 3.0%. Net proceeds are intended for research and development and general corporate purposes.
On September 28, 2026, BeyondSpring agreed, subject to the agreement’s terms and conditions, to transfer its wholly owned BeyondSpring Ltd. to Biolin Investment Limited. As consideration, the investor is to conduct and complete the China portion of DUBLIN-4; BeyondSpring will receive related data, and its indirect SEED Therapeutics stake will be reduced. Separately, Nasdaq gave BeyondSpring until March 16, 2027, to regain compliance with the $1.00 minimum closing bid-price requirement by meeting it for at least 10 consecutive business days, after 30 consecutive business days below the threshold. The notice had no immediate effect on the listing.
BeyondSpring Inc. (BYSI) is conducting a primary offering of 800,000 ordinary shares to Ray Beauty Group Limited at $2.50 per share, raising an estimated $2 million in net proceeds after expenses. The company plans to use the cash to fund its research and development programs and for general corporate purposes, which may include clinical trial and commercial spending, working capital, debt repayment and potential acquisitions.
Shares outstanding are expected to increase from 40,322,320 to 41,122,320 as of the referenced date, modestly diluting existing holders. As of September 30, 2025, BeyondSpring reported a net tangible book value of $(0.49) per share, which would improve to $(0.43) per share on an as-adjusted basis after the offering, but investors buying in this deal face an immediate dilution of $2.93 per share. The company remains a clinical-stage biopharmaceutical developer centered on its lead oncology asset, Plinabulin, and additional preclinical immune agents.